Skip to main content
Premium Trial:

Request an Annual Quote

NIH Awards Omicia, Johns Hopkins $187,000 to Study Genetics of Cardiovascular Disease

NEW YORK (GenomeWeb News) - Omicia said today it has received a small business technology transfer grant worth $187,700 from the National Institutes of Health to support a collaboration with Johns Hopkins University to study the genetic underpinnings of cardiovascular disease.
 
The award from the National Heart, Lung, and Blood Institute will support a project conducted by Omicia and JHU biomedical engineering researcher Joel Bader that aims to identify genetic risk factors for cardiovascular disease "by drawing parallels from systematic genetic screens performed on fruit flies and other model organisms," the company said.
 
These screens will be used to determine phenotypes for relevant genes in each of the model organisms.
 
The collaborators will also develop data-mining algorithms that will help select sets of genes that lead to similar phenotypes in different organisms and which are likely to play significant roles in human health and disease, Omicia said.
 
Bader said in a statement that the collaborators "aim to significantly advance the understanding of the genetic basis of cardiovascular disease, paving the way towards the earliest possible diagnosis and the most appropriate therapeutic options."

The Scan

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.